Director
Dr. Sudeep Gupta is a Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, India. Dr. Gupta obtained his MBBS degree from All India Institute of Medical Sciences (AIIMS) in New Delhi in 1992. He completed his Postgraduate (MD degree) in internal medicine in 1994.
International Collaborations: Arizona State University, U.S.A.
Kings College London, U.K.
George Washington University, U.S.A.
National Collaborations: Centre for Development of Advanced Computing (CDAC), Pune.
Indian Institute of Technology (IIT-B), Bombay
National Centre for Cellular Sciences, (NCCS) Pune
National Institute of Biomedical Genomics (NIBMG), Kalyani
The primary focus of clinician scientist laboratory (CSL) is on understanding the biological role of hypoxia in cancer metastasis & cancer spread, clonal evolution of a tumour leading to therapy resistance, and developing novel blood based assays to monitor tumour burden and response to therapy. Our laboratory comprises of an interdisciplinary group of surgical oncologists, medical oncologists, pathologists, basic scientists, and data scientists collaborating on addressing questions formulated from clinical observations. Our laboratory uses a bedside - to bench - to bedside approach where-in observations from the clinics generate a hypothesis. We then test this hypothesis using pre-clinical assays. Big data generated from patient samples using OMICS technologies integrate with, and inform, these pre-clinical assays. We use a variety of model systems including in-vitro cell-based assays, in-vivo animal studies and 3D organoid cultures to address our research questions. The eventual goal of our laboratory is to translate our pre-clinical findings in the laboratory into relevant interventions addressing clinical problems. Our laboratory is the nodal laboratory for the multi-omics endocrine hormone resistance study in breast cancer initiative under the aegis of the Virtual National Cancer Institute (VNCI) endeavor by the Department of Biotechnology, Govt. of India.
The proluton study… more
funded by the Tata Memorial Centre explores the role of peri-operative… more
is funded by the Department of… more
funded by the Tata Memorial Centre, aims to investigate the utility of… more
is a flagship study funded by the Department of Biotechnology, Governm… more
aims to identify the role of AP-1 (Activator protein-1) subunit comple… more
Prof. Surgical Oncology, Tata Memorial Hospital
Prof. Surgical Oncology, Tata Memorial Hospital
Associate Professor, Department of Surgical Oncology, Breast Services Tata Memorial Hospital
Associate Professor, Department of Surgical Oncology, Breast Services Tata Memorial Hospital
Professor, Department of Surgical Oncology, Breast Services, and Director, Tata Memorial Centre
Professor, Department of Surgical Oncology, Breast Services, and Director, Tata Memorial Centre
Professor, Department of Medical Oncology and Director, Advanced Centre for Treatment, Research and Education in Cancer
Professor, Department of Medical Oncology and Director, Advanced Centre for Treatment, Research and Education in Cancer
Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK
Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort. J Contemp Brachytherapy. 2018 Feb;10(1):47-57. doi: 10.5114/jcb.2018.74137. Epub 2018 Feb 28.
Phase III randomized trial comparing intravenous to oral iron in patients with cancer- related iron deficiency anemia not on erythropoiesis stimulating agents.Asia Pac J Clin Oncol. 2018 Apr;14(2):e129-e137. doi: 10.1111/ajco.12762. Epub 2017 Aug 28.
Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer.South Asian J Cancer. 2018 Apr-Jun;7(2):102-105. doi: 10.4103/sajc.sajc_111_18.